Vancouver, BC – October 27, 2025 – Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) has been granted a significant patent by the United States Patent and Trademark Office (USPTO) for its advanced contact-free breath analysis device and method. This latest patent, U.S. Patent No. 18/1729,658, underscores the company’s commitment to innovation in breath-sampling technology and further solidifies its position in the rapidly evolving landscape of drug and alcohol detection.
The newly patented technology is central to Cannabix’s BreathLogix device platform, featuring a sophisticated dual-mode system that incorporates both contactless breath capture and traditional mouthpiece functionality. This innovation allows for fast, reliable, and hygienic testing without the need for direct physical contact, a critical advancement for public health and safety applications.
A Leap Forward in Breath Analysis Technology
The core of this patent lies in Cannabix’s proprietary advancements in breath capture and analysis. The BreathLogix system is designed for seamless integration into various environments, offering features such as unmanned device operation, real-time visual feedback, and adaptive airflow control. The system intelligently adjusts its internal mechanisms to ensure accuracy and efficiency, regardless of the sampling method employed. This technological leap not only enhances user experience but also addresses critical hygiene concerns, making it ideal for widespread deployment.
“We are very pleased to add this important innovation to our patent portfolio,” stated Rav Mlait, CEO of Cannabix Technologies. “This patent grant enhances Cannabix’s leadership in the world of breath sampling and detection techniques, paving the way for significant advancements in safety and compliance across multiple industries.”
Broad Applications Across Diverse Sectors
The wide-ranging utility of Cannabix’s patented technology opens doors to numerous applications. Its compact and modular design makes it exceptionally well-suited for integration into everyday settings such as vehicles, workplaces, and public kiosks. Furthermore, the system’s capabilities are highly valuable for law enforcement agencies, workplace safety programs, and public health monitoring initiatives. The ability to conduct rapid, non-invasive testing without physical contact offers a significant advantage in scenarios requiring frequent or widespread screening.
This patent reinforces Cannabix’s strategic focus on developing cutting-edge solutions that cater to a growing demand for accurate and efficient impairment detection. The company has a history of pioneering advancements, particularly in the detection of THC, the primary psychoactive component in cannabis, as well as in alcohol screening devices.
Strategic Growth and Brand Innovation
Cannabix Technologies has been actively pursuing technological advancements and market penetration. The company’s BreathLogix platform has seen recent commercial successes, including deliveries to an oilfield transportation services company and a European maritime shipping company, underscoring the demand for its alcohol screening solutions. The company has also established strategic partnerships, such as its development agreement with Omega Laboratories Inc., aimed at commercializing its marijuana breathalyzer technology. These efforts collectively contribute to strengthening Cannabix’s brand and its reputation for delivering innovative cannabis and alcohol testing products.
The company’s dedication to research and development is evident in its growing intellectual property portfolio, which includes previous patent allowances and pending applications for its analytical devices. By securing this key U.S. patent, Cannabix not only protects its inventive technologies but also enhances its competitive edge and its ability to bring new cannabis products and testing solutions to market.
Future Outlook
With this new patent, Cannabix Technologies Inc. is well-positioned to capitalize on the increasing global need for advanced breath analysis solutions. The company’s ongoing development of innovative technologies, coupled with its strategic market entries, signals a promising future as it continues to lead in breath-sampling and detection techniques, contributing to safer workplaces and public spaces.
Cannabix Technologies Inc. is listed on the CSE, OTC PINK, and Frankfurt stock exchanges, alongside other notable cannabis and technology companies.
